X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (241660) 241660
Publication (24171) 24171
Book Review (3236) 3236
Book Chapter (998) 998
Newsletter (872) 872
Conference Proceeding (499) 499
Magazine Article (204) 204
Dissertation (163) 163
Book / eBook (87) 87
Newspaper Article (81) 81
Web Resource (44) 44
Data Set (35) 35
Government Document (35) 35
Trade Publication Article (19) 19
Paper (17) 17
Reference (12) 12
Streaming Video (9) 9
Presentation (7) 7
Transcript (4) 4
Journal / eJournal (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (163788) 163788
index medicus (109833) 109833
male (87556) 87556
animals (80960) 80960
female (79609) 79609
middle aged (48486) 48486
adult (45521) 45521
mice (39346) 39346
aged (30224) 30224
oncology (28881) 28881
expression (25015) 25015
immunology (23140) 23140
rats (22184) 22184
inflammation (21948) 21948
necrosis-factor-alpha (21810) 21810
pharmacology & pharmacy (21735) 21735
biochemistry & molecular biology (20082) 20082
treatment outcome (20079) 20079
cancer (19130) 19130
cell biology (18733) 18733
therapy (17368) 17368
analysis (16629) 16629
cytokines (16599) 16599
research (15989) 15989
apoptosis (15774) 15774
tnf-alpha (15673) 15673
health aspects (14702) 14702
tumor necrosis factor-alpha - metabolism (14665) 14665
interferon-alpha - therapeutic use (14603) 14603
disease models, animal (13858) 13858
care and treatment (13662) 13662
gastroenterology & hepatology (13552) 13552
article (13349) 13349
neurosciences (13210) 13210
alpha (12940) 12940
medicine, research & experimental (12845) 12845
activation (12541) 12541
proteins (12459) 12459
cells (12070) 12070
tumor-necrosis-factor (12032) 12032
cells, cultured (12021) 12021
cell line, tumor (11985) 11985
gene expression (11955) 11955
tumor necrosis factor-alpha - antagonists & inhibitors (11767) 11767
adolescent (11564) 11564
time factors (11153) 11153
risk factors (10828) 10828
oxidative stress (10690) 10690
disease (10433) 10433
hematology (10240) 10240
recombinant proteins (10185) 10185
research article (10056) 10056
signal transduction (9890) 9890
physiological aspects (9882) 9882
mice, inbred c57bl (9846) 9846
drug therapy, combination (9733) 9733
rheumatology (9569) 9569
prognosis (9536) 9536
medicine (9523) 9523
medicine & public health (9502) 9502
endocrinology & metabolism (9478) 9478
dose-response relationship, drug (9474) 9474
in-vitro (9365) 9365
interferon-alpha (9251) 9251
gene-expression (9246) 9246
antiviral agents - therapeutic use (9017) 9017
interferon (8620) 8620
in-vivo (8466) 8466
nf-kappa-b (8445) 8445
surgery (8183) 8183
rats, sprague-dawley (8119) 8119
aged, 80 and over (8030) 8030
genetic aspects (7991) 7991
tumors (7936) 7936
multidisciplinary sciences (7665) 7665
factor-alpha (7642) 7642
immunohistochemistry (7625) 7625
young adult (7546) 7546
rodents (7526) 7526
infliximab (7517) 7517
child (7420) 7420
rheumatoid-arthritis (7301) 7301
cell line (7297) 7297
drug therapy (7212) 7212
medicine, general & internal (7000) 7000
pathology (6929) 6929
hepatitis c, chronic - drug therapy (6915) 6915
inhibition (6914) 6914
apoptosis - drug effects (6769) 6769
antibodies, monoclonal - therapeutic use (6683) 6683
double-blind (6577) 6577
abridged index medicus (6338) 6338
retrospective studies (6216) 6216
infection (6201) 6201
interferon-alpha - administration & dosage (6087) 6087
tumor necrosis factor (6077) 6077
prospective studies (6060) 6060
follow-up studies (6043) 6043
urology & nephrology (6007) 6007
mutation (5964) 5964
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (44) 44
Online Resources - Online (40) 40
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Regis College - Stacks (1) 1
Scarborough Hospital - Online (1) 1
St. Augustine's Seminary - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (232193) 232193
German (2131) 2131
French (1894) 1894
Chinese (1693) 1693
Japanese (1460) 1460
Russian (1177) 1177
Spanish (1030) 1030
Polish (498) 498
Italian (316) 316
Korean (190) 190
Hungarian (156) 156
Portuguese (116) 116
Dutch (103) 103
Czech (83) 83
Turkish (72) 72
Croatian (57) 57
Danish (56) 56
Swedish (53) 53
Ukrainian (48) 48
Serbian (40) 40
Hebrew (33) 33
Norwegian (33) 33
Romanian (27) 27
Finnish (26) 26
Bulgarian (19) 19
Slovak (15) 15
Persian (8) 8
Slovenian (7) 7
Arabic (5) 5
Bosnian (4) 4
Greek (3) 3
Lithuanian (3) 3
Estonian (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Genetics, ISSN 0340-6717, 11/2011, Volume 130, Issue 5, pp. 583 - 605
Dominant negative genetic disorders, in which a mutant allele of a gene causes disease in the presence of a second, normal copy, have been challenging since... 
Human Genetics | Gene Function | Molecular Medicine | Biomedicine | Metabolic Diseases | SMALL INTERFERING RNA | DOUBLE-STRANDED-RNA | DYSTROPHY PROTEIN-KINASE | SICKLE-CELL-ANEMIA | GENETICS & HEREDITY | CENTRAL-NERVOUS-SYSTEM | ALPHA-SYNUCLEIN | BLOOD-BRAIN-BARRIER | HUNTINGTONS-DISEASE | MAMMALIAN-CELLS | MYOTONIC-DYSTROPHY | Parkinson Disease - therapy | Muscular Dystrophies - therapy | Humans | Anemia, Sickle Cell - drug therapy | Parkinson Disease - drug therapy | Spinocerebellar Ataxias - therapy | Genetic Diseases, Inborn - therapy | Molecular Targeted Therapy | Muscular Dystrophies - genetics | Amyotrophic Lateral Sclerosis - drug therapy | Huntington Disease - therapy | Neoplasms - therapy | Genes, Dominant | Neoplasms - genetics | RNA Interference | Spinocerebellar Ataxias - drug therapy | Huntington Disease - drug therapy | Spinocerebellar Ataxias - genetics | Amyotrophic Lateral Sclerosis - therapy | Amyotrophic Lateral Sclerosis - genetics | Alzheimer Disease - therapy | Muscular Dystrophies - drug therapy | Alzheimer Disease - drug therapy | Rats | Clinical Trials as Topic | Parkinson Disease - genetics | Neoplasms - drug therapy | Anemia, Sickle Cell - therapy | Point Mutation | Animals | Huntington Disease - genetics | Mice | Alzheimer Disease - genetics | Genetic Diseases, Inborn - drug therapy | Anemia, Sickle Cell - genetics | Genetic Therapy - methods | Enzymes | Gene mutations | Gene therapy | Catalytic RNA | Health aspects | Genes | Drugs | Parkinson's disease | Neurodegenerative diseases | Tumor cells | RNA-mediated interference | Amyotrophic lateral sclerosis | Antisense RNA | Drug delivery | Single-nucleotide polymorphism | Huntington's disease | Muscular dystrophy | Mutation | Ribozymes | Alzheimer's disease | Movement disorders | Cancer | Pharmaceuticals
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 07/2016, Volume 107, Issue 7, pp. 1013 - 1017
The RCC‐SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC)... 
overall survival | renal cell carcinoma | prognostic factors | interferon‐α | The Era of molecular targeted therapy | Interferon-α | Overall survival | Renal cell carcinoma | Prognostic factors | interferon-α | SURVIVAL | STAT3 POLYMORPHISM | FOLLOW-UP | SORAFENIB | PHASE-III TRIAL | RADICAL NEPHRECTOMY | HYPERCALCEMIA | INVASION | ONCOLOGY | SUNITINIB | interferon-alpha | JAPANESE PATIENTS | Kidney Neoplasms - genetics | Prognosis | Humans | Middle Aged | Carcinoma, Renal Cell - genetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Case-Control Studies | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | STAT3 Transcription Factor - genetics | Carcinoma, Renal Cell - pathology | Interferon-alpha - therapeutic use | Survival Rate | Treatment Outcome | Interferon-alpha - administration & dosage | Polymorphism, Single Nucleotide - genetics | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Cohort Studies | Thrombocytopenia | Demography | Cell survival | Disease | Cytokines | Research funding | Stat3 protein | Histology | Single-nucleotide polymorphism | Metastasis | Multivariate analysis | Patients | Lymph nodes | Metastases | Hypercalcemia | Studies | Medical prognosis | Kidney cancer | Growth patterns | Interferon | Clear cell-type renal cell carcinoma | Original
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2013, Volume 59, Issue 3, pp. 434 - 441
Journal Article
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2013, Volume 159, Issue 2, pp. 86 - 96
Background: Telaprevir (TVR) plus peginterferon-alpha 2a (PEG-IFN-alpha 2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic... 
Vertex pharmaceuticals and janssen pharmaceuticals | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | PREDICTORS | ALPHA-2A PLUS RIBAVIRIN | BOCEPREVIR | HCV | ANEMIA | VIROLOGICAL RESPONSE | ASSOCIATION | HIV-1 | Recombinant Proteins - therapeutic use | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - pharmacokinetics | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Ribavirin - pharmacokinetics | Interferon-alpha - pharmacokinetics | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Double-Blind Method | Antiviral Agents - therapeutic use | Oligopeptides - pharmacokinetics | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Polyethylene Glycols - pharmacokinetics | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | HIV Infections - complications | Interferon-alpha - adverse effects | Antiviral agents | Patient outcomes | Dosage and administration | Drug therapy, Combination | Research | Hepatitis C | Drug therapy | HIV infection | Index Medicus | Abridged Index Medicus
Journal Article